{"filing":{"accession_number":"0001129928-26-000035","cik":"0001129928","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"oncy-20260522.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000035/oncy-20260522.htm"},"events":[{"id":10518,"run_id":9223,"accession_number":"0001129928-26-000035","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces presentation of translational data from clinical studies (GOBLET and AWARE-1) at a major medical conference (ASCO Annual Meeting), describing pelareorep's mechanism of action and immune system effects. While this represents material clinical/scientific progress for a biotech company, it does not fit neatly into more specific event categories (not an earnings release, not a regulatory approval, not a material impairment or litigation). The announcement of clinical data presentation at a major conference would be material to investors assessing the company's pipeline and therapeutic potential.","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":6848,"accession_number":"0001129928-26-000035","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces presentation of translational data from clinical studies (GOBLET and AWARE-1) at a major medical conference (ASCO Annual Meeting), describing pelareorep's mechanism of action and immune system effects. While this represents material clinical/scientific progress for a biotech company, it does not fit neatly into more specific event categories (not an earnings release, not a regulatory approval, not a material impairment or litigation). The announcement of clinical data presentation at a major conference would be material to investors assessing the company's pipeline and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:25:41.867087+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6848,"accession_number":"0001129928-26-000035","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces presentation of translational data from clinical studies (GOBLET and AWARE-1) at a major medical conference (ASCO Annual Meeting), describing pelareorep's mechanism of action and immune system effects. While this represents material clinical/scientific progress for a biotech company, it does not fit neatly into more specific event categories (not an earnings release, not a regulatory approval, not a material impairment or litigation). The announcement of clinical data presentation at a major conference would be material to investors assessing the company's pipeline and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:25:41.867087+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-05-22"}]}